|
|
Blood, 15 November 2005, Vol. 106, No. 10, pp. 3609-3617.
Prepublished online as a Blood First Edition Paper on August 4, 2005; DOI 10.1182/blood-2005-04-1489.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
Thorsten Stühmer,
Manik Chatterjee,
Martin Hildebrandt,
Pia Herrmann,
Hella Gollasch,
Christian Gerecke,
Sebastian Theurich,
Luisa Cigliano,
Rudolf A. Manz,
Peter T. Daniel,
Kurt Bommert,
Lyubomir T. Vassilev, and
Ralf C. Bargou
From the Department of Internal Medicine II, Division of Hematology and Oncology, University Clinics Würzburg, Würzburg, Germany; the Department of Hematology, Oncology, and Tumorimmunology, Robert Rössle Cancer Clinic at the Max Delbrück Center for Molecular Medicine, Charité-Berlin University Medicine, Campus Buch, Berlin, Germany; Discovery Oncology, Hoffmann-La Roche, Nutley, NJ; and Department of Humoral Immunology, German Rheumatism Research Center, Berlin, Germany.
Mutation of p53 is a rare event in multiple myeloma, but it is unknown if p53 signaling is functional in myeloma cells, and if targeted nongenotoxic activation of the p53 pathway is sufficient to kill tumor cells. Here, we demonstrate that treatment of primary tumor samples with a small-molecule inhibitor of the p53–murine double minute 2 (MDM2) interaction increases the level of p53 and induces p53 targets and apoptotic cell death. Significantly, given the importance of the bone marrow microenvironment for the support and drug resistance of myeloma cells, tumor cells undergo effective apoptosis also in the presence of stromal cells, which themselves appear to tolerate exposure to nutlin-3. The in vitro toxicity of nutlin-3 was similar to that of the genotoxic drug melphalan. Because nutlin-mediated p53 activation is not dependent on DNA damage, MDM2 antagonists may help to avoid or reduce the severe genotoxic side effects of chemotherapeutic agents currently used to treat multiple myeloma. Therefore, MDM2 antagonists may offer a new treatment option for this disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Kranz, C. Dohmesen, and M. Dobbelstein
BRCA1 and Tip60 determine the cellular response to ultraviolet irradiation through distinct pathways
J. Cell Biol.,
October 23, 2008;
182(1):
197 - 213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Zhu, L. Gu, F. Li, and M. Zhou
Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells
Mol. Cancer Ther.,
May 1, 2008;
7(5):
1101 - 1109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Secchiero, F. Corallini, E. Rimondi, C. Chiaruttini, M. G. di Iasio, A. Rustighi, G. Del Sal, and G. Zauli
Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells
Blood,
February 1, 2008;
111(3):
1287 - 1294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Cheok, A. Dey, and D. P. Lane
Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis: a Potent Drug Combination
Mol. Cancer Res.,
November 1, 2007;
5(11):
1133 - 1145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Kan, J. T. Patton, G. R. Stark, and M. W. Jackson
p53-Mediated Growth Suppression in Response to Nutlin-3 in Cyclin D1 Transformed Cells Occurs Independently of p21
Cancer Res.,
October 15, 2007;
67(20):
9862 - 9868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Drakos, A. Thomaides, L. J. Medeiros, J. Li, V. Leventaki, M. Konopleva, M. Andreeff, and G. Z. Rassidakis
Inhibition of p53-Murine Double Minute 2 Interaction by Nutlin-3A Stabilizes p53 and Induces Cell Cycle Arrest and Apoptosis in Hodgkin Lymphoma
Clin. Cancer Res.,
June 1, 2007;
13(11):
3380 - 3387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Jiang, N. Pabla, R. F. Murphy, T. Yang, X.-M. Yin, K. Degenhardt, E. White, and Z. Dong
Nutlin-3 Protects Kidney Cells during Cisplatin Therapy by Suppressing Bax/Bak Activation
J. Biol. Chem.,
January 26, 2007;
282(4):
2636 - 2645.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Wang and J. Robbins
Heart Failure and Protein Quality Control
Circ. Res.,
December 8, 2006;
99(12):
1315 - 1328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Wade, E. T. Wong, M. Tang, J. M. Stommel, and G. M. Wahl
Hdmx Modulates the Outcome of P53 Activation in Human Tumor Cells
J. Biol. Chem.,
November 3, 2006;
281(44):
33036 - 33044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Van Maerken, F. Speleman, J. Vermeulen, I. Lambertz, S. De Clercq, E. De Smet, N. Yigit, V. Coppens, J. Philippe, A. De Paepe, et al.
Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
Cancer Res.,
October 1, 2006;
66(19):
9646 - 9655.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Barbieri, P. Mehta, Z. Chen, L. Zhang, A. Slack, S. Berg, and J. M. Shohet
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death.
Mol. Cancer Ther.,
September 1, 2006;
5(9):
2358 - 2365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kojima, M. Konopleva, T. McQueen, S. O'Brien, W. Plunkett, and M. Andreeff
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia
Blood,
August 1, 2006;
108(3):
993 - 1000.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. E. Kay
p53 activation comes to the rescue in CLL
Blood,
May 15, 2006;
107(10):
3815 - 3816.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Secchiero, E. Barbarotto, M. Tiribelli, C. Zerbinati, M. G. di Iasio, A. Gonelli, F. Cavazzini, D. Campioni, R. Fanin, A. Cuneo, et al.
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)
Blood,
May 15, 2006;
107(10):
4122 - 4129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Patton, L. D. Mayo, A. D. Singhi, A. V. Gudkov, G. R. Stark, and M. W. Jackson
Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3.
Cancer Res.,
March 15, 2006;
66(6):
3169 - 3176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
